Dr. Tarek M. Sabagh

About Tarek M. Sabagh

Education:

• Obtained a Medical degree (MD) from the American University of Beirut Faculty of Medicine, Lebanon, in 2007.
• Completed Residency in Internal Medicine at the University of Cincinnati Medical Center, Ohio (2008-2011).
• Undertook a Fellowship in Gastroenterology and Hepatology at the University of Cincinnati Medical Center, Ohio (2011-2014).

Experience:

• Currently practices as a gastroenterologist at Miami Valley Hospital South.

Area of expertise

Affiliated Hospitals

Miami Valley Hospital South

Miami Valley Hospital North

Clinical Trials Tarek M. Sabagh is currently running

BRAF-Targeted Therapy

for Colon Cancer

This phase II/III trial compares treatment with encorafenib and cetuximab to usual care (patient observation) for reducing the chance of cancer recurrence after standard surgery and chemotherapy in patients with BRAF-mutated stage IIB-III colon cancer. Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Giving encorafenib and cetuximab after standard surgery and chemotherapy may be more effective at reducing the chance of cancer recurrence compared to the usual patient observation.

Recruiting1 award Phase 2 & 3

Stereotactic Radiation + Immunotherapy

for Kidney Cancer

This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.

Recruiting1 award Phase 221 criteria

More about Tarek M. Sabagh

Other Doctors you might be interested in

Frequently asked questions